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TITLE: CLINICAL UTILITY OF EXOME SEQUENCING IN THE PRENATAL DIAGNOSIS OF 
CONGENITAL ANOMALIES. 
Fionnuala Mone, Elizabeth Quinlan-Jones, Mark D Kilby 
ABSTRACT 
Advances in prenatal genomics have enabled the assessment of not only the sub-
microscopic structure of chromosomes using chromosomal microarray analysis, but also the 
detection of “pathogenic variants” to the resolution of a single base pair with the use of 
next generation sequencing.  Research is emerging on the additional prenatal diagnostic 
yield that exome sequencing offers when structural fetal anomalies are detected on 
ultrasound examination, in particular with defining prognosis and recurrence of anomalies.  
Primarily assessed using fetal DNA obtained by invasive techniques (amniocytes or chorionic 
villi), this technology is progressing into a non-invasive approach using maternal plasma.  
There are several challenges, to be addressed before this technology can be introduced into 
routine clinical practice.  These are primarily technical and interpretational but also relate to 
service provision; cost-effectiveness; turn-around time; patient acceptability and ethical 
dilemmas.  With adequate pre- and post-test counselling many of these challenges may be 
overcome and such counselling will be multi-disciplinary, involving clinical geneticists, 
genetic scientists, paediatricians, perinatal pathologists and fetal medicine specialists.  
There is therefore a need for obstetricians to have an understanding of the application, 
advantages and challenges of such technologies before introduction into clinical practice.   
KEY WORDS: NEXT GENERATION SEQUENCING; EXOME SEQUENCING; PRENATAL; 
MONOGENTIC DISORDERS; FETAL ANOMALY; PAGE STUDY 
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INTRODUCTION 
Fetal structural anomalies anomalies (FSA) complicate up to 5% of pregnancies.1  
Quantitative Fluorescence-Polymerase Chain Reaction (QF-PCR), conventional karyotype 
and chromosomal microarray (CMA) will detect up to 40% of the underlying chromosomal 
aetiology associated with FSAs.  With advances in genomic technology, theoretically, we 
have the ability to increase the diagnostic yield of testing through the use of Next 
Generation Sequencing (NGS). These techniques allow examination of the genome down to 
one base pair, facilitating the diagnosis of monogenic disorders (Figure 1 and Box 1).  The 
introduction of such technology into prenatal diagnosis will require complex clinical 
pathway development with multi-disciplinary team (MDT) working and communication.  
 
 
<Insert Figure 1 and Box 1> 
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DISCUSSION 
Approaches in Next Generation Sequencing 
NGS is typically applied in proband cases where single major or multiple FSAs are identified 
on prenatal ultrasound scanning and standard prenatal testing strategies identify no 
chromosomal anomalies.1   Common techniques include: 
(i) Clinical or targeted exome sequencing – specific exonic regions of interest are 
sequenced and a panel of genes are tested which are known to be associated with 
specific phenotypes;2   
(ii) Whole Exome Sequencing (now referred to as ‘exome sequencing (ES)’)  - coding 
exons of all known disease coding genes are interrogated  (Figure 2) and; 
(iii) Whole Genome Sequencing (WGS), where the whole genome inclusive of non-
coding intronic regions is assessed.  This technique is beyond the scope of this 
review and has yet to be assessed in prenatal diagnosis.3   
NGS (primarily ES in the prenatal setting) may be performed to analyse fetal tissue/cells 
obtained by invasive prenatal testing or in certain specific cases, as a non-invasive prenatal 
diagnostic (NIPD) test.4  Testing should ideally performed as a “trio” analysis (fetus 
[proband] and both parents) to aid in the assignment of variant pathogenicity .5  CMA will 
delineate copy number variants and mosaicism in the case of an array-comparative genomic 
hybridisation technique, with the addition of genotyping (uniparental disomy, loss of 
heterozygosity and consanguinity) in the case of a single nucleotide polymorphism array 
technique.  NGS has the ability to combine assessment of all of these measures in addition 
to the determination of single nucleotide variation.   
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<Insert Figure 2> 
Processing and interpretation of variants 
This is a complex process requiring experienced and specialist bioinformatic teams.  It is one 
of the practical ‘barriers’ to introducing ES into clinical medical practice.  Variant processing 
and interpretation involves a stepwise workflow, an example of which is demonstrated in 
Figure 3.  Paramount to this workflow, is input of the MDT.5   Following pre-test counselling 
and informed consent, DNA is extracted and library preparation using target enrichments 
are used to optimise coverage. ES can then be performed using a selected platform (e.g. 
Ilumina GAIIx®) by a sequencing by synthesis approach to determine the sequence of the 
exonic regions.6  Following the sequencing process, masses of data regarding base alignment 
is produced and this is subsequently re-aligned and annotated by means of a bioinformatics 
pipeline, comparing the test sequence to an updated version of the reference genome.2  
Variants are then filtered and interpreted by means of an in silico tool to determine variants 
predicted to affect the protein sequence or exon splicing through use of prediction 
programs. Variants are graded using criteria including characteristics such as allele 
frequency of <5%; functional impact i.e. if they are synonymous and non-protein altering; 
nucleotide conservation between species and; the finding of a variant within clinical 
databases that are of benign consequence and/or are not related to the phenotype. 
Remaining variants are compared to the parental genome to assess if they are de novo (i.e. 
a variant which has developed for the first time during meiosis as opposed to one which is 
inherited from one/both parent(s)), which would imply pathogenicity.6,7  
 
<Insert Figure 3> 
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Variants are graded using the Association of Clinical Genetic Science criteria by means of a 
five-class system ranging from benign or non-pathogenic, to variants of uncertain 
significance (VUS) to clearly pathogenic. Once or if a variant is identified the next step is to 
validate the variant, often using Sanger sequencing.3   
 
Reporting of variants 
ES may identify the presence of VUS.  As knowledge of variant interpretation evolves, it is 
likely that the incidence of true VUS will reduce, as has been the demonstrated with CMA 
reporting.8 ES may also unveil secondary findings (SF); variants considered to be medically 
actionable but unrelated to the primary indication for testing and often relating to late 
onset conditions, such as cancer. In the UK current practice gives patients the option of 
‘opting out’ which is determined during pre-test counselling.  In the prenatal setting, such 
secondary findings are not typically revealed in the research setting.9   Incidental findings 
(ICF) are variants, which are discovered unexpectantly and are unrelated to phenotype 
referred.  Currently these are also not routinely reported.10 Presently, in the UK, NHS 
England is exploring the introduction of prenatal ES before the end of 2019 and with 
expected clinical pathway ‘turnaround’ duration of approximately 21 days.  This is 
achievable but has health economic implications, not least because of laboratory and 
bioinformatic workforce implications. 
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Advantages 
The primary advantage of the prenatal application of NGS is that it allows, in a proportion of 
cases, the revelation of a causative variant allowing an improved prognostic definition for 
the fetus.  Parents will be able make a prospective, autonomous decision about their 
pregnancy and an early-prenatal identification may allow the future development of fetal 
therapies.11  A defined single gene aetiology aids in counselling relating to recurrence risk, 
opening opportunities for pre-implantation genetic diagnosis and future prenatal testing.12 
Following trio analysis it is often discovered that most pathogenic variants are de novo in 
origin, however the potential of gonadal mosaicism cannot be out-ruled hence prenatal 
testing in subsequent pregnancies for both inherited pathogenic variants and those felt to 
be de novo may be offered once the pathogenic variant of the initial affected pregnancy is 
known.  In paediatric practice, the diagnostic yield of ES (of approximately 25%) has been 
well established in various cohort series with congenital malformations and developmental 
morbidity3.  
 
Diagnostic yield 
There are limited prenatal cohort studies which have assessed the diagnostic utility of ES 
and more research is needed before it can be applied in the routine clinical setting.13,14  Two 
of the largest prenatal studies in structurally abnormal fetuses thus far suggest an ES 
diagnostic yield of 7.5-8.5%.15,16  The largest of these, the Prenatal Assessment of Genomes 
and Exomes (PAGE) study has presently prospectively assessed 610 fetuses with structural 
anomalies on ultrasound through ES trio analysis and found it to have an additional 
diagnostic yield of 8.5%.14  As noted by the smaller cohort study from the US by  Wapner, et 
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al. the diagnostic yield was greater where there were multiple FSAs present on ultrasound, 
where the yield was a high as 15%.15,16 It also varied between different phenotypic sub-
groups with pathogenic variants more common in fetuses with hydrops, cardiac or skeletal 
abnormalities but a low diagnostic yield in those with only an isolated elevated nuchal 
translucency and no pathogenic variants identified in the co-existence of isolated renal or 
thoracic abnormalities.  The PAGE study unveiled several novel diagnoses and had a rate of 
VUS of 3.9%.16   Accurate and detailed phenotyping (including dysmorphological 
examination) has been shown to optimise the accuracy of ES, as evident from its’ efficacy 
when testing is based upon post-mortem findings with a reported diagnostic yield of 37% in 
a subset of the PAGE study cohort where fetuses underwent autopsy (n=27).17  Additionally, 
where prenatal cases are selected specifically by a geneticist (highlighting a high suspicion of 
an underlying pathogenic variant) the yield is significantly higher, at 47% in one study 
(n=15).18  Where cases are pre-selected based upon the severity of the anomaly, as opposed 
to the unselected population assessed in PAGE, diagnostic yields, particularly in the 
presence of skeletal and brain anomalies are greater.4,18 The utilisation of ES is dependent 
upon the accurate recognition of phenotypic patterns to target fetuses with the greatest risk 
of having an underlying pathogenic variant.  This requires input from a clinical geneticist 
with expertise in dysmorphology to recognise phenotypical patterns and classify features 
appropriately.   
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Challenges 
The challenges of prenatal ES are focused within four primary areas; (i) technical – there are 
sample considerations such as DNA quality and quantity and the presence of maternal cell 
contamination.  Tissue culturing and the use of appropriate library preparation can optimise 
processing but there is a risk of clonal selection.2 ES does not analyse intronic regions or 
assess for epigenetic modifications and depending upon the depth of base pair coverage, all 
exonic regions may not be fully assessed with the risk of false negative results and a further 
65% of FSAs which go unexplained.  As the prenatal phenotype is based upon detailed 
ultrasonography this may be associated with poor true diagnostic potential.2 (ii) service 
provision – genetic services are limited and training of the MDT in the prenatal setting will 
be required before NGS can be introduced routinely.; (iii) cost – the cost effectiveness of 
prenatal ES is not yet known although this is currently being evaluated as part of the PAGE 
Study collaboration.19 In line with Moore’s Law, the costs associated with NGS technologies 
have reduced significantly since inception and are optimised by the multiplex nature and as 
further understanding of the technology evolves over time.5; (iv) turnaround time - studies 
have suggested that an 11-41 day turnaround time is possible, and this should improve as 
more sophisticated bioinformatic analysis pipelines are developed and understanding 
improves.5 The prenatal setting is unique as timely results are required to facilitate decision 
making with regards continuation of pregnancy.  It is anticipated that the 100,000 genome 
project (not primarily focused upon prenatal anomalies) and subsequent PAGE study 
findings will address these pitfalls and offer solutions to optimise the process. 9,19 
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Ethical considerations 
Primary ethical concerns with regards NGS focus around several topics: 
 (i) ES may not identify the primary cause for investigation and may uncover ICFs or SFs, 
which can have implications for both the open future of the child and for the wider family20;  
 (ii) non-paternity or consanguinity may be revealed;  
(iii) ownership of genetic results and the rights of the wider family to access this 
information21;  
(iv) NGS is an evolving technology and with time new pathogenic variants will be identified.  
There are challenges in relation to who is responsible for such re-analysis and reporting to 
the child11;  
(v) limiting diversity in society  
There are consensus recommendations to aid with managing such scenarios.2,22  
 
Recommendations 
The American College of Medical Genetics and American College of Obstetricians and 
Gynecologists agree that ES may be considered when targeted testing for a specific 
phenotype fails to identify a cause for multiple fetal anomalies, where a genetic condition is 
likely and following consultation with a clinical geneticist.23,24   A joint position statement 
from the International Society of Prenatal Diagnosis, Society of Maternal Fetal Medicine and 
Perinatal Quality Foundation states that the routine use of NGS as a prenatal diagnostic test 
cannot currently be supported until adequate validation studies are performed. Outside a 
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research setting, this it must only be considered on a case-by-case setting with the input of 
appropriate expertise [Box 2].  The statement also highlights the need for; (i) trio analysis 
(testing of biological parents); (ii) consideration of “panels” vs. genome wide applications; 
(iii) adequate pre and post-test counselling with separate consent from both parents and; 
(iv) appropriate laboratory quality standards.13  
 
<Insert Box 2> 
 
Non-invasive application 
NGS technologies can be performed on cffDNA.25 Thus far, this approach has been assessed 
for two main applications.  Firstly, prenatal design of a bespoke NIPD test for a typically de 
novo (where gonadal mosaicism cannot be out-ruled) or a paternally inherited autosomal 
dominant variant in a previous pregnancy to assess for recurrence in an index 
pregnancy.26,27 Proband (in this context, fetal) and parental DNA is required.  The second 
application for NIPD is with use of a gene panel where a genetic syndrome is suspected, 
such as the case of an FGFR3 panel assessing for achondroplasia, hypochondroplasia and 
thanatophoric dysplasia.28 Limitations of this approach relate to cost and the need for a fast 
turn-around time.29 Technological challenges include having an appropriate quantity of fetal 
DNA, in addition to challenges of assessing highly polymorphic regions the presence of 
pseudogenes and homologous regions or maternal mosaicism.   
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12 
12 
      CONCLUSION 
In the presence of FSAs identified using prenatal ultrasound, the application of ES can 
obtain a genetic diagnosis in over 8% of cases compared to standard techniques.  The 
diagnostic yield is optimised by the presence of multiple anomalies, involvement of 
genetic expertise and accurate phenotyping.  This approach can be applied to both fetal 
tissue and more recently maternal plasma with assessment of the fetal DNA fraction.  
The information provided from NGS serves valuable in autonomous parental decision 
making with regards continuation of pregnancy, perinatal planning and counselling as to 
recurrence risk.  Although currently primarily a research tool, NGS will likely come into 
routine practice in the near future.  While there are challenges, which need to be 
addressed, with time and on-going research it is hoped than many of these may be 
overcome, notably in relation to turnaround time, interpretation, cost and clinical 
provision as part of an ethical framework.   
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FIGURE AND TABLE LEGENDS 
Figure 1 and Box 1 Diagnostic precision of prenatal chromosomal/genetic testing   
Figure 2 Exome sequencing output  
Reproduced with permission of Carss K & Hurles M, Sanger Institute, Cambridge, UK 
Figure 3 Sample workflow pattern for variant interpretation in prenatal exome 
sequencing.2,6 
Box 2 International Society of Prenatal Diagnosis, Society of Maternal Fetal Medicine and 
Perinatal Quality Foundation recommendations of when prenatal ES may be considered18 
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WHOLE GENOME AND EXOME SEQUENCING IN PRENATAL DIAGNOSIS  
 
Fionnuala Mone, Elizabeth Quinlan-Jones, Mark D Kilby 
 
ABSTRACT 
Advances in prenatal genomics have enabled the assessment of not only the sub-
microscopic structure of chromosomes through chromosomal microarray analysis, but also 
the detection of pathogenic variants to the resolution of one base pair with the use of next 
generation sequencing.  Research is emerging on the additional prenatal diagnostic yield 
which whole exome sequencing offers when structural fetal anomalies are detected on 
ultrasound examination.  Primarily assessed using fetal DNA obtained by invasive techniques 
(amniocytes or chorionic villi), this technology is progressing into a non-invasive approach 
using maternal plasma.  There are several challenges, to be addressed before this 
technology could be introduced into routine clinical practice.  These are primarily technical 
and interpretational but also relate to service provision; cost-effectiveness; turn-around 
time; patient acceptability and ethical dilemmas.  With adequate pre- and post-test 
counselling many of these challenges may be overcome.  However, it is likely that this 
counselling will be multi-disciplinary and will involve geneticists, genetic scientists, 
paediatricians, perinatal pathologists and fetal medicine specialists.  There is a need for 
obstetricians to be educated about the application, advantages and challenges of such 
technologies before introduction into clinical practice.   
KEY WORDS: NEXT GENERATION SEQUENCING; WHOLE EXOME SEQUENCING; PRENATAL; 
MONOGENTIC DISORDERS; FETAL ANOMALY; PAGE STUDY 
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INTRODUCTION 
Fetal structural anomalies anomalies (FSA) complicate up to 5% of pregnancies (depending 
upon the population studied).  Quantitative Fluorescence-Polymerase Chain Reaction (QF-
PCR), conventional karyotype and chromosomal microarray (CMA) will detect up to 40% of 
the underlying chromosomal aetiology associated with structural anomalies.  With advances 
in genomic technology, theoretically, we have the ability to increase the diagnostic yield of 
testing through the use of Next Generation Sequencing (NGS) technologies. This technique 
has a resolution down to one base pair, facilitating the diagnosis of monogenic disorders 
(Figure 1 and Box 1).  Current advances in the use of NGS in the research field means that 
we will soon see a shift in the use of this technology into clinical practice.  Already, there is a 
move towards using these tests in paediatrics to assess developmental disorders with 
interesting data sets being reported. The potential introduction of such technology into 
prenatal diagnosis will require complex clinical pathway development with multi-disciplinary 
team working and communication.  
 
 
<Insert Figure 1 and Box 1> 
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DISCUSSION 
 
Approaches in Next Generation Sequencing 
Next generation sequencing is typically applied in proband cases where single major or 
multiple FSAs are identified on prenatal ultrasound scanning and standard prenatal testing 
strategies (i.e. QF-PCR or CMA) identify no chromosomal anomalies.1  Common techniques 
used in NGS include: 
(i) Clinical or targeted exome sequencing – where specific exonic regions of interest are 
sequenced and a panel of genes are tested which are known to be associated with 
specific phenotypes;2   
(ii) Whole Exome Sequencing (WES) - whereby coding exons of all known disease 
coding genes are interrogated (1-2% of human genome and 85% of variants that 
cause single gene disorders) (Figure 2) and; 
(iii) Whole Genome Sequencing (WGS), where the whole genome inclusive of non-
coding intronic regions is assessed.3   
Such techniques (primarily exome sequencing in the prenatal setting) may be performed to 
analyse fetal tissue or in certain specific cases, through analysis of placental cell-free fetal 
DNA (cffDNA) as a non-invasive prenatal diagnostic (NIPD) test using maternal plasma.4  
Testing should ideally performed as a “trio” analysis (fetus and both parents) to aid in the 
assignment of variant pathogenicity.5  CMA can delineate copy number variants and 
mosaicism in the case of an array-comparative genomic hybridisation technique, with the 
addition of genotyping (uniparental disomy, loss of heterozygosity and consanguinity) in the 
case of a single nucleotide polymorphism array technique.  NGS has the ability to combine 
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 5 
assessment of all of these measures in addition to the determination of single nucleotide 
variation.   
<Insert Figure 2> 
Processing and interpretation of variants 
This is a complex process requiring experienced and specialist bioinformatic teams.  It is one 
of the practical ‘barriers’ to introducing exome sequencing into clinical medical practice.  
Variant processing and interpretation involves a stepwise workflow, an example of which is 
demonstrated in Figure 3.  Paramount to this workflow, is the input of the multidisciplinary 
team inclusive of clinical scientists, geneticists, bioinformaicians, genetic counsellors and 
fetal medicine specialists.5   Following adequate pre-test counselling, informed consent and 
provision of a trio sample, DNA is extracted and library preparation using target 
enrichments such as Amplicon® are used to optimise coverage. WES can then be performed 
using a selected platform (e.g. Ilumina GAIIx®) by a massive parallel sequencing and bridge 
amplification technique whereby sequencing by synthesis is performed utilising 
fluorescently labelled bases to determine the sequence of the exonic regions.6  Following 
the sequencing process, masses of data regarding base alignment is produced and this is 
subsequently re-aligned and annotated by means of a bioinformatics pipeline, comparing 
the test sequence to an updated version of the reference genome (currently GRCh37 human 
reference version).2  Variants are typically then filtered and interpreted by means of an in 
silico tool or a similar in house version to determine variants predicted to affect the protein 
sequence or exon splicing through use of prediction programs.  As yet there are no currently 
recognised programmes or clinical databases validated for use in the prenatal setting, hence 
those used in rare Mendelian disorders such as DECIPHER [https://decipher.sanger.ac.uk] 
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 6 
are used.  Variants are evaluated or graded using criteria including characteristics such as 
allele frequency of <5%; functional impact i.e. if they are synonymous and non-protein 
altering; nucleotide conservation between species and; the finding of a variant within 
clinical databases that are of benign consequence and/or are not related to the phenotype.  
Such variants can then be excluded from the analysis and the remainder are subsequently 
compared to the parental genome to assess if they are de novo (i.e. a variant which has 
developed for the first time during meiosis as opposed to one which is inherited from 
one/both parent(s)), which would imply pathogenicity.6,7  
 
<Insert Figure 3> 
 
Variants are classed or graded using the Association of Clinical Genetic Science criteria by 
means of a five-class system ranging from benign or non-pathogenic, to variants of 
uncertain significance (VUS) to clearly pathogenic.  Joint American College of Medical 
Genetics and Genomic and Association for Molecular Pathology standards for the 
interpretation of sequence variants have been formally adopted for use in United Kingdom 
(UK) laboratories to assist clinical scientists with classification of sequence variants 
identified prenatally.7-9 Once or if a variant is identified the next step is to validate the 
variant, often using Sanger sequencing or an alternative technique such as multiplex ligand-
dependent probe amplification in a local / regional genetics laboratory.3  
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Reporting of variants 
WES may identify the presence of VUS.  One of the options for parents is to receive VUS at a 
later time, or not at all, depending on the judgement of a multidisciplinary team.  As 
knowledge of variant interpretation evolves, it is likely that the incidence of true VUS will 
reduce, as has been the demonstrated with CMA reporting.10 WES may also unveil 
secondary findings (SF); variants considered to be medically actionable but unrelated to the 
primary indication for testing and often relating to late onset conditions such as cancer and 
cardiac disease.  The American College of Medical Genetics and Genomics recommend that 
diagnostic laboratories actively look for and report on such variants in the case of 59 
preselected disease-associated genes.11 In the UK, there is no such equivalent guidance and 
current practice gives patients the option of ‘opting out’ which is determined during pre-test 
counselling.  In the prenatal setting, such secondary findings are not typically revealed in the 
research setting.12   Incidental findings (ICF) are variants, which are discovered 
unexpectantly and are unrelated to phenotype referred.  Currently these are also not 
routinely reported, however again guidance is lacking.13  Presently, in the UK, NHS England 
is exploring the introduction of prenatal WES before the end of 2019 and with expected 
pathway ‘turnaround’ duration of approximately 21 days.  
 
Advantages 
The primary advantage of the prenatal application of NGS is that it allows, in a proportion of 
cases, the revelation of a causative variant allowing an improved prognostic definition for 
the fetus.  Parents will be able make a prospective, autonomous decision about their 
pregnancy and an early-prenatal identification may allow the future development of fetal 
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 8 
therapies.14  A defined single gene aetiology aids in counselling relating to recurrence risk in 
subsequent pregnancies, opening opportunities for pre-implantation genetic diagnosis and 
future prenatal testing.15 Following trio analysis it is often discovered that most pathogenic 
variants are de novo in origin, however the potential of gonadal mosaicism can not be out-
ruled hence prenatal testing in subsequent pregnancies for both inherited pathogenic 
variants and those felt to be de novo may be offered once the pathogenic variant of the 
initial affected pregnancy is known.  In paediatric practice, the diagnostic yield of WES (of 
approximately 25%) has been well established in various cohort series with congenital 
malformations and developmental morbidity3.  The diagnostic yield has been demonstrated 
to be greatest for children with an underlying neurological phenotype or intellectual 
disability, with a high prevalence of pathogenic autosomal dominant de novo mutations.16,17  
NGS is not currently part of routine clinical practice and it is the aim of the current ‘proof of 
principle’ 100,000 genomes project in the UK to act as a bridge for NGS into mainstream 
clinical practice for the diagnosis of rare Mendelian disorders.12 
 
Diagnostic yield 
There are limited prenatal cohort studies which have assessed the diagnostic utility of WES 
and more research is needed before it can be applied in the routine clinical setting.18,19 A 
recent review of the literature suggested a diagnostic yield over conventional chromosomal 
assessment, ranging from 6.2 to 80%5. 
 The variation appears dependent on: 
(i) the type of analysis (trio or solo proband); 
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 9 
(ii) clinical or whole exome sequencing; 
(iii) the number, certainty of diagnosis and type of anomalies present and; 
(iv) if the test was performed on a selected or unselected population.5     
The application of ‘targeted’ prenatal exome sequencing has yielded promising results, 
notably in the area of suspected skeletal dysplasia where use of a panel of 240 known 
skeletal dysplasia gene mutations in appropriately phenotyped fetuses, yielded  a diagnostic 
rate of 81% in selected cases.4  Two of the largest prenatal studies in structurally abnormal 
fetuses thus far suggest a WES diagnostic yield of 7.5-8.5%.20,21  The largest of these, the 
Prenatal Assessment of Genomes and Exomes (PAGE) study assessed 610 fetuses with 
structural anomalies on ultrasound through WES trio analysis and found it to have an 
additional diagnostic yield of 8.5%.19  As noted by the smaller cohort study from the US by  
Wapner, et al. the diagnostic yield was greater where there were multiple FSAs present on 
ultrasound, where the yield was a high as 15%.21 It also varied between different phenotypic 
sub-groups with pathogenic variants more common in fetuses with hydrops, cardiac or 
skeletal abnormalities but a low diagnostic yield in those with only an isolated elevated 
nuchal translucency and no pathogenic variants identified in the co-existence of isolated 
renal or thoracic abnormalities.  The PAGE study unveiled several novel diagnoses and had a 
rate of VUS of 3.9%.21  
 
Accurate and detailed phenotyping (including dysmorphological examination) has been 
shown to optimise the accuracy of WES, as evident from its’ efficacy when testing is based 
upon post-mortem findings with a reported diagnostic yield of 37% in a subset of the PAGE 
study cohort where fetuses underwent autopsy (n=27).22  Additionally, where prenatal cases 
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 10 
are selected specifically by a geneticist (highlighting a high suspicion of an underlying 
pathogenic variant) the yield is significantly higher, at 47% in one study (n=15).23  Where 
cases are pre-selected based upon the severity of the anomaly, as opposed to the 
unselected population assessed in PAGE, diagnostic yields, particularly in the presence of 
skeletal and brain anomalies are greater.4,23  In addition to the clinical benefit of obtaining a 
diagnosis, WES has the benefit of being an automated multiplex technology which can 
reduce bias in interpretation and in time reduce the cost of testing, although this is yet to be 
determined.  Table 1 outlines the advantages and challenges posed by the application of 
prenatal WES.  
 
Challenges 
The challenges of prenatal WES are focused within four primary areas; (i) technical – there 
are sample considerations such as DNA quality and quantity and the presence of maternal 
cell contamination which must be overcome when performing WES.  Tissue culturing and 
the use of appropriate library preparation can optimise processing but there is a risk of 
clonal selection.2 WES does not analyse intronic regions or assess for epigenetic 
modifications and depending upon the depth of base pair coverage, all exonic regions may 
not be fully assessed with the risk of false negative results and a further 65% of FSAs which 
go unexplained (Figure 4).  As the prenatal phenotype is based upon detailed 
ultrasonography this may be associated with poor true diagnostic potential.2 Currently, 
Sanger sequencing is used to validate WES findings, which has additional resource 
implications; (ii) service provision – genetic services are limited and training of the multi-
disciplinary team in the prenatal setting will be required before NGS can be introduced into 
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routine clinical practice.  Counselling is challenging in a prenatal setting due to ethical 
considerations and the difficulty in knowing how penetrant a pathogenic variant may be or 
as to how severe a child may be affected; (iii) cost – the cost effectiveness of prenatal WES 
is not yet known although this is currently being evaluated as part of the PAGE Study 
collaboration.24 In line with Moore’s Law, the costs associated with NGS technologies have 
reduced significantly since inception and are optimised by the multiplex nature and as 
further understanding of the technology evolves over time.  There are also significant costs 
related to data storage and re-interpretation5; (iv) turnaround time - studies have suggested 
that an 11-41 day turnaround time is possible, and this should improve as more 
sophisticated bioinformatic analysis pipelines are developed and understanding improves.5 
The prenatal setting is unique as timely results are required to facilitate decision making 
with regards continuation of pregnancy.  It is anticipated that the 100,000 genome project 
(no primarily focused upon prenatal anomalies) and subsequent PAGE study findings will 
address these pitfalls and offer solutions to optimise the process.  In addition to elucidating 
the relative contribution of different forms of genetic variation in prenatal FSAs and 
determine the cost effectiveness of prenatal WES, the PAGE study also aims to catalyse the 
adoption, by the National Health Service in the UK, of prenatal diagnostic sequencing 
through translation of acquired knowledge, rigorous health economic assessment, and 
establishment of an ethical social science framework for clinical implementation.24 
 
<Insert Figure 4> 
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Ethical considerations 
Primary ethical concerns with regards NGS focus around several topics, which must be the 
focus of counselling and consent for patients prior to undergoing WES: 
 (i) WES may not identify the primary cause for investigation and may uncover ICFs or SFs – 
revealing the findings of pathogenic variants which may lead to adult-onset disease can 
have implications for both the open future of the child and for the wider family25; Certainly 
in the UK PAGE study these were á priori not reported, unless they were on a specific 
predefined gene list. 
 (ii) non-paternity or consanguinity may be revealed;  
(iii) ownership of genetic results and the rights of the wider family to access this information 
in the so called ‘joint-account’ concept26;  
(iv) NGS is an evolving technology and with time new pathogenic variants will be identified.  
There are challenges in relation to who is responsible for such re-analysis and reporting to 
the child14;  
(v) limiting diversity in society – are we on the brink of creating a selected designer 
population?  Adequate pre and post-test counselling may ease the management of some of 
these dilemmas and there are consensus recommendations to aid with managing such 
ethical scenarios.2,27  
 
<Insert Table 1> 
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Recommendations 
The American College of Medical Genetics and American College of Obstetricians and 
Gynecologists agree that WES may be considered when targeted testing for a specific 
phenotype fails to identify a cause for multiple fetal anomalies, where a genetic condition is 
likely and following consultation with a clinical geneticist.28,29   A joint position statement 
from the International Society of Prenatal Diagnosis, Society of Maternal Fetal Medicine and 
Perinatal Quality Foundation acknowledges the challenges which the prenatal application 
and prospective use of NGS may pose.  This document states that the routine use of NGS as 
a prenatal diagnostic test cannot currently be supported until adequate validation studies 
are performed.  While recognising that NGS is currently being performed in a research 
setting, outside this it must only be considered on a case-by-case setting with the input of 
appropriate expertise.  The statement also highlights the need for; (i) trio analysis (testing of 
biological parents); (ii) consideration of “panels” vs. genome wide applications; (iii) 
adequate pre and post-test counselling with separate consent from both parents and; (iv) 
appropriate laboratory quality standards.  Situations where WES could be considered are 
demonstrated in Box 2.18 There is currently no recognised international guideline for the use 
of prenatal NGS in routine clinical practice and the cost-effectiveness of its’ application has 
yet to be assessed.  
 
<Insert Box 2> 
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Non-invasive application 
NGS technologies can be performed on cffDNA isolated from maternal plasma.30  Once a 
plasma sample is obtained, the fetal DNA fraction is quantified and assessed.  Sequencing 
may then be performed using Amplicon® technology.  Thus far, this approach has been 
assessed for two main applications.  Firstly, prenatal design of a bespoke NIPD test for a 
typically de novo (where gonadal mosaicism cannot be out-ruled) or a paternally inherited 
autosomal dominant variant in a previous pregnancy to assess for recurrence in an index 
pregnancy.31,32  Assessment for an autosomal recessive disorder is also feasible using a 
haplotype analysis approach, however the parents must have different mutations.  Proband 
(in this context, fetal) and parental DNA is required.  The second application for NIPD is with 
use of a gene panel where a genetic syndrome is suspected, such as the case of an FGFR3 
panel assessing for achondroplasia, hypochondroplasia and thanatophoric dysplasia.33  A 
non-invasive approach is favourable as it is a safe option for patients, however the focus of 
testing is upon obtaining appropriate validation and accreditation, which will take time.  
Limitations of this approach relate to cost and the need for a fast turn-around time.34  
 
Additionally there are technological challenges, which include having an appropriate 
quantity of fetal DNA, in addition to challenges of assessing highly polymorphic regions the 
presence of pseudogenes and homologous regions or maternal mosaicism.   
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Whole genome sequencing 
The primary focus of this review has been on exome sequencing, mainly because WGS has 
not been formally assessed in the prenatal setting.  However, WGS facilitates sequencing of 
the entire genome inclusive of deep intronic regions, non-coding RNA and mitochondrial 
DNA, extending to the detection of copy number variants and structural rearrangements, 
hence may improve diagnostic yield and can serve as an ‘all in’ genetic test. Our 
understanding and ability to interpret intronic variants is limited, hence the current primary 
focus is on WES.35 The efficacy of WGS has been assessed in the setting of rare Mendelian 
disease in children and suggests an additional diagnostic yield over WES of 8.7% although 
how this will translate into prenatal practice is as yet unknown and it is postulated that the 
rate of VUS may be more significant.36  
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      CONCLUSION 
In the presence of fetal structural anomalies identified using prenatal ultrasound, the 
application of WES can obtain a genetic diagnosis in over 8% of cases compared to 
standard techniques.  The diagnostic yield is optimised by the presence of multiple 
anomalies, involvement of genetic expertise and accurate phenotyping.  This approach 
can be applied to both fetal tissue and more recently maternal plasma with assessment 
of the fetal DNA fraction.  The information provided from NGS serves valuable in 
autonomous parental decision making with regards continuation of pregnancy, perinatal 
planning and counselling as to recurrence risk.  Although currently primarily a research 
tool, NGS will likely come into routine practice in the near future.  While there are 
challenges, which need to be addressed, with time and on-going research it is hoped 
than many of these may be overcome, notably in relation to turnaround time, 
interpretation, cost and clinical provision as part of an ethical framework.   
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FIGURE AND TABLE LEGENDS 
Figure 1 and Box 1 Diagnostic precision of prenatal chromosomal/genetic testing   
Figure 2 Same whole exome sequencing output Sequence output  
Reproduced with permission of Carss K & Hurles M, Sanger Institute, Cambridge, UK 
Figure 3 Sample workflow pattern for variant interpretation in prenatal exome 
sequencing.2,6 
Figure 4 – The diagnostic yield of prenatal tests in the presence of a structural fetal anomaly 
Table 1 Advantages and challenges of prenatal whole exome sequencing over standard 
genetic testing (MCC=maternal cell contamination; NIPD=non-invasive prenatal diagnosis) 
Box 2 International Society of Prenatal Diagnosis, Society of Maternal Fetal Medicine and 
Perinatal Quality Foundation recommendations of when prenatal WES may be considered18 
 
 
 
 
 
 
 
 
 
 
Situations where WES may be considered prenatally include:  
1. Fetal anomalies or a single major anomaly suggestive of a genetic disorder, but  
microarray is negative    
2. No microarray result is available, but the fetus exhibits anomalies strongly suggestive 
of a single gene disorder (multidisciplinary review required)   
3. Previous undiagnosed fetus (or child) from either parent, with single or multiple 
anomalies suspicious for a genetic syndrome that has now recurred in the current 
pregnancy   
4. Karyotype and microarray in the current pregnancy have not yielded a diagnosis     
5. If samples are unavailable from previously affected offspring or the current 
pregnancy, consider offering parents sequencing to determine if they may be 
carriers for an autosomal recessive disorder   
6. History of recurrent stillbirths with negative karyotype and/or microarray, where the 
fetus is exhibiting a similar pattern of anomalies 
Box 2
Figure 1 and Box 1
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